News & Events

News Archive

April 9, 2018

Morphotek Announces Agreement to License its Proprietary Eribulin-Linker Payload to Bliss Biopharmaceutical Co., LTD. for Development of A Therapeutic Antibody-Drug Conjugate (ADC)*
Read More

January 24, 2018

Morphotek to Present Poster on CA125 Suppression of Humoral Immune Responses of Antibodies at the Upcoming ASCO-SITC Clinical Immuno-Oncology Symposium
Read More

January 10, 2018

Morphotek Announces FDA Acceptance of Investigational New Drug Application for Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202
Read More

December 11, 2017

Morphotek and Rockefeller University Form a Sponsored Research Agreement to Study the Immunosuppressive Effects of the Tumor Shed Antigen CA125 and its Potential Impact in Future Patient Therapies
Read More

December 7, 2017

Morphotek to Present its Proprietary RESPECT Antibody-Drug Conjugate (ADC) Technology at the Upcoming Antibody Engineering & Therapeutics Conference in San Diego
Read More

December 4, 2017

Morphotek Announces Initiation of Phase 1 Study of Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202 in Solid Tumors with Folate Receptor Alpha Expression
Read More

November 14, 2017

Morphotek to Present its Proprietary RESPECT Antibody Drug Conjugate (ADC) Technology at the Upcoming 9th Annual PEGS Europe in Lisbon
Read More

September 19, 2017

Morphotek to Present Preclinical Data on Antibody-Drug Conjugate MORAb-202 at the Upcoming 8th Annual World ADC in San Diego
Read More

September 6, 2017

Morphotek Announces Collaboration Agreement with the Johns Hopkins University to Research and Develop Novel Monoclonal Antibody-Based Therapies Targeting Missplicing-Associated Surface Antigens
Read More

September 5, 2017

Morphotek, Inc. Announces an Agreement with Fujirebio Diagnostics, Inc to Commercialize the CA125 II Assay as A Companion Diagnostic for Farletuzumab
Read More

Displaying results 1-10 (of 139)
 |<  < 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10  >  >| 

News & Events > News Archive